



Disclaimer

Forward-looking Statements

CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to obtain additional funding to develop our product candidates; our ability to satisfy any requirements imposed by the FDA (or its foreign equivalents); the impact of COVID-19 on our clinical trials, preclinical activities and our ability to raise future financing; our ability to continue our relationship with Toray; the need to obtain and retain regulatory approval of our products, both in the United States and in countries deemed necessary for future trials; our ability to complete our clinical trials in a timely fashion and within our expected budget and resources; compliance with obligations under intellectual property licenses with third parties; our ability to commercialize our product candidates; market acceptance of our products; and our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our products. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Bluejay's actual results to differ from those contained in the forward-looking statements, see Item 1A. "Risk Factors" in Bluejay's most recent Form 10-K filed with the Securities and Exchange Commission, as updated by the Company's subsequent Quarterly Reports on Form 10-Q.



Bluejay Diagnostics is focused on improving patient outcomes in critical care settings using Symphony:

Delivering a cost efficient, rapid, near-patient product for triage and treatment guidance



The Symphony System

Bluejay is Focused on Improving Patient Outcomes in Hospital/LTAC* Settings

Using Symphony, a cost efficient, rapid, near-patient product for triage and monitoring of disease progression

 Novel, Proprietary, Diagnostic Platform Focused on cost-effective, rapid, near-patient products for triage and m disease progression in hospital/long-term acute care setting Uses whole blood (without any pre-processing steps) 	nonitoring
 Lead Product Candidate, the Symphony IL-6 Test, in the Clinic Pre-Submission filing package sent to the FDA in January, 2022 Clinical studies underway to determine patient acuity for sepsis triage and support <i>De Novo</i> FDA marketing application, intended by YE:22 	and monitoring
 Pipeline of Symphony Test applications utilize the same proprietary inst development pathway Represent \$925MM hospital, \$2-3B LTAC market opportunity 	rument &
 Waterfall Commercial Strategy Large, well-respected clinical testing sites are built-in commercial custor Reagent-rental model and DRG-based reimbursement simplifies adoption 	
 Funded to Execute on Plan \$17.1MM in cash as of March 31, 2022, sufficient to fund operations be regulatory approval and initial commercialization of the Symphony IL-6 Capital efficient model 	


*LTAC = Long Term Acute Care The Symphony System and Sy

The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA

The Symphony System: Technology Platform

Analyzer and Cartridge basics

The Symphony Analyzer



- · Same operational matrix irrespective of the test performed
- Same detection method
- 6 different samples or 6 different tests, simultaneously

Symphony Cartridge




- No additional chemicals
- No pre-processing of the sample
- ELISA = Enzyme-Linked Immunosorbent Assay

The Symphony platform will be leveraged by developing tests for other indications

Lengthy Testing Time Reduces Utility for triage/Treatment Guidance

For use in hospital/long-term acute care (LTAC*) settings to provide triage/treatment guidance




Current Testing Methods:

- Testing systems are very large, so they need to be run in a central lab setting
- The whole process, from blood draw to results, takes 4-48hr*** this is a long time in a critical care setting
- Systems require highly trained, expensive laboratory technicians to operate and maintain them



Symphony Transforms Care Through Rapid, Near-Patient Testing

Enables Physicians to make better treatment decisions for patients with life-threatening illnesses



Symphony's Differentiated Features:

- The System can test whole blood samples (without the need for any pre-test processing)
- Symphony is a desk-top system, so tests can be run in critical care settings, near the patient's beside
- Results are provided quickly to make triage/treatment decisions (time to results ~20 minutes)

Symphony System Potential Advantages¹ v. Other Selected Tests

Uses well-accepted ELISA² chemistry plus unique microfluidics/nanotechnology platform

Potential Advantages	Bluejay's Symphony System	Beckman Coulter	Siemens	Roche
Near Patient	Near patient	Central Lab	Central Lab	Central lab
Test System Size	Desk Top	Very Large	Very Large	Very Large
Sample type	Whole blood	Serum/plasma	Serum/plasma	Serum/plasma
Sample Pre-process	No	Yes	Yes	Yes
Time from test to result	~20 minutes	4-48hr ³	4-48hr ³	4-48hr ³
Requires Dedicated Personnel (phlebotomist/MedTech)	No	Yes	Yes	Yes
System/Infrastructure Cost ⁴	\$	\$\$\$	\$\$\$	\$\$\$

1. Source: Bluejay Diagnostics market research

3, Bluejay/Industry information, pending the location of the testing lab

2. ELISA = Enzyme-Linked Immunosorbent Assay



Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2022 8

Symphony Product Pipeline Targets Multi-Billion Dollar Markets*

Plan to expand the testing menu to include other well-validated critical care biomarkers

Product Pipeline Commercial Rights	Research	Development	Clinical Testing	Regulatory	Estimated Market Opportunity*
Symphony [™] IL-6 Test To determine patient acuity for sepsis triage/monitoring Bluejay Diagnostics			>>>		Hospitals: \$925M + LTAC: \$2-3B
Symphony [™] hsTNT/I To determine patient acuity with chest pain Bluejay Diagnostics and Toray Industries		>>>			
Symphony [™] NT-proBNP To determine patient acuity with chest pain Bluejay Diagnostics and Toray Industries		>>			Hospitals: \$3.6B

Ongoing investment in Symphony System to improve user interface and support user adoption

New Tests Will Follow the IL-6 Development Pathway



Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2022 9

First Product: Symphony IL-6 Test for sepsis triage and monitoring

Measuring IL-6 could help medical professionals make earlier and better triage/treatment decisions

Interleukin-6 (IL-6) is a Principal Inflammatory Cytokine Released During Trauma or Infection

- It appears early on as a "first responder" during infection or inflammation
- Important in sepsis, neutropenic sepsis, multi-organ failure, cancers, rheumatoid arthritis, autoimmune disorders, cardiovascular diseases

Current tests have received Emergency Use Authorization (EUA) for use in COVID-19 sepsis/RUO* for arthritis

 Beckman-Coulter, Roche and Siemens (EUA: COVID-sepsis) and Toray (RUO: arthritis)



*RUO – Research Use Only ** Bluejay/Industry information

Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2022 10

IL-6 is Following a Well-Established Clinical Testing Pathway

Studies will document Symphony performance versus standard of care

Elements of Clinical Testing Program: Expected to Completed by Q3:22 (using ~250 subjects):

Testing Program	Testing Sites	
Reference Range Study Cut-Off Value Study Cut-Off Validation Study Analytical Testing	UT Southwestern Medical Center Zale Lipshy Pavilion Hospital	William P. Clements Jr. University Hospital


Regulatory Plan

Milestone	Target Timing
Initiate Testing Program at UT Southwestern Testing Sites	Q4:2021: Complete
File FDA Pre-submission application	January 2022: Complete
Conduct an expanded Testing Program	Q1-Q3:2022
File a marketing application with the FDA* for the use of the Symphony IL-6 Test for sepsis triage/monitoring	YE:22



Launch Plan Starts by Converting Bluejay's Test Sites to Commercial Sites

Existing multi-location healthcare testing sites are built-in initial commercial customers




bluejay

transactions to be processed via a 3rd party lessor

Manufacturing Overview

Contract Manufacturing Agreements in Place with Toray and Sanyoseiko



- Multinational company with 96+ years of manufacturing experience
- Toray will manufacture cartridges for 3 years



- An FDA-registered medical device manufacturer with more than 50 years of global experience in medical devices manufacturing
- Manufacturing the Symphony Analyzer and cartridges



Management & Advisors: Leadership, Diagnostic & Product Launch Expertise

Indranil "Neil" Dey CEO and Co-founder	 Involved in introducing Her2neu test for Herceptin (>\$1.2 billion revenue), Lead numerous global teams Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary, MBA (Fulbright Scholar) from Cambridge University, UK 		
Kenneth Fisher Chief Financial Officer	 Responsible for finance, investor relations, accounting and administrative operations with support to commercial/BD BA, Business Administration, Isenberg School of Management, UMass Amherst; New England School for Financial Studies. CPA 		
Jason Cook Chief Technology Officer	 Responsible for Bluejay's product development and manufacturing 15+ years in POC/ diagnostics product development, Ph.D. in Biomedical Engineering, University of Texas at Austin 		
Kevin Vance Chief Commercial Officer	 In charge of Bluejay's worldwide direct sales and strategic partnerships. Prior Chief BD Executive for Vibra Healthcare BS, Industrial Engineering & Operations Research from UMass Amherst; MBA, Western New England University 		
 Edwin Rule, VP Regulatory, Quality, Compliance with support to the Symphony System product development team. BS, Mechanical Engineering, Northeastern U.; MS, Marketing/Technological Innovation, WPI, ASQ Six Sigma Green Belt 			
 Mark Feinberg Chief Medical Advisor Guide Bluejay's clinical development programs, provide strategic medical and scientific leadership Associate Professor, Harvard Medical School/Cardiovascular, Brigham & Women's; Medical College of Pennsylvania 			
IMPATH	TEXAS Savings Bank Fresenius Fresenius Fresenius Fresenius Fresenius Fresenius Fresenius Founding Member, Mass General Brigham		

Savings Bank

Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2022 14



The University of Texas at Austin

Board of Directors

Douglas C. Wurth Chairman	 20 year career at J.P. Morgan Chase (CEO of the International Private Bank & Alternative Investments, Asset Management) B.A Notre Dame University; J.D. University of Virginia School of Law, practiced law at Skadden, Arps, Meagher and Flom
Indranil "Neil" Dey CEO	 Involved in introducing Her2neu test for Herceptin (>\$1.2 billion revenue) and introduction of Erbitux (>\$1.15 billion revenue) Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary and MBA (Fulbright Scholar) from Cambridge University, UK
Svetlana Dey	 Co-founder of Bluejay, President & CEO of LMBRI LLC, 15 years+ of management experience in healthcare industry Masters Degree in Mathematics from the State University of Mari El Republic, Russia
Donald R. Chase	 35 years, Executive roles in well-known community banks in Springfield, MA. and Millyard, NH B.S., Accounting, Western New England University, Springfield, MA
Fred S. Zeidman	 50+ years of corporate advisory experience. Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University
Gary Gemignani	 Experience in life sciences, public companies, accounting/ finance. Senior executive/leadership roles starting at Arthur Anderson & Co Also Solta Medical Corporation, Acacia Pharma Group plc, Biodel Inc., Prudential Financial, Gentium, Novartis, Wyeth
J.P.Morgan Skadden	1 VILLE WILL AND A CONTRACT OF

Upcoming Milestones

Highlights Symphony IL-6 Test Development and Pipeline Expansion

Milestone	Estimated Timing	
Symphony IL-6: Reference Range Study: Complete enrollment in 1 st study cohort	Q1:22: Complete	
Report Q4:2021 Financial Results/Update on Pipeline Programs	March 2022: Complete	
Report Q1:22 Financial Results/Update on Pipeline Programs	April 2022: Complete	
Symphony IL-6: Finish Clinical Program	Q3:22	
Symphony IL-6: Submit FDA marketing application	YE:22	
Report Q2:22 Financial Results/Update on Pipeline Programs	July 2022	
Report Q3:22 Financial Results/Update on Pipeline Programs	October 2022	

Potential Presentation of Clinical Results in Peer-Reviewed Setting Could Provide Additional Milestones



Bluejay is Focused on Improving Patient Outcomes in Hospital/LTAC* Settings

Using Symphony, a cost efficient, rapid, near-patient product for triage and monitoring of disease progression

Novel, Proprietary, Diagnostic Platform	 Focused on cost-effective, rapid, near-patient products for triage and monitoring disease progression in hospital/long-term acute care setting Uses whole blood (without any pre-processing steps)
Lead Product Candidate, the Symphony IL-6 Test, in the Clinic	 Pre-Submission filing package sent to the FDA in January, 2022 Clinical studies underway to determine patient acuity for sepsis triage and monitoring and support <i>De Novo</i> FDA marketing application, intended by YE:22
Multi-Billion Opportunity	 Pipeline of Symphony Test applications utilize the same proprietary instrument & development pathway Represent \$925MM hospital, \$2-3B LTAC market opportunity
Waterfall Commercial Strategy	 Large, well-respected clinical testing sites are built-in commercial customers Reagent-rental model and DRG-based reimbursement simplifies adoption for hospitals
Funded to Execute on Plan	 \$17.1MM in cash as of March 31, 2022, sufficient to fund operations beyond anticipated regulatory approval and initial commercialization of the Symphony IL-6 Test Capital efficient model

*LTAC = Long Term Acute Care The Symphony System and Sy

The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA

Bluejay Diagnostics is focused on improving patient outcomes in critical care settings using Symphony:

Delivering a cost efficient, rapid, near-patient product for triage and treatment guidance



The Symphony System

Contact

Bluejay Diagnostics, Inc.



360 Massachusetts Avenue, Suite 203, Acton, MA 01720



Toll-free: 844.327.7078 Main: 978.631.4884



ir@bluejaydx.com